首页 | 本学科首页   官方微博 | 高级检索  
检索        

吉西他滨联合顺铂一线治疗晚期NSCLC的疗效及相关因素分析
引用本文:王秋明,林英城,林雯,王鸿彪,林文照,林穗玲.吉西他滨联合顺铂一线治疗晚期NSCLC的疗效及相关因素分析[J].肿瘤防治研究,2011,38(8):940-943.
作者姓名:王秋明  林英城  林雯  王鸿彪  林文照  林穗玲
作者单位:515031 广东汕头,汕头大学医学院附属肿瘤医院内科(*现工作单位: 514031广东梅州,梅州市人民医院肿瘤化疗三科)
摘    要:目的评价吉西他滨联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的疗效,并探讨影响化疗疗效及预后的相关因素。方法回顾性分析113例至少接受2周期吉西他滨联合顺铂方案(GP方案)化疗的ⅢB~Ⅳ期NSCLC患者,评价疗效及不良反应;Kaplan-Meier法分析生存情况,Cox回归法进行多因素预后分析。结果GP方案的总有效率43.8%,临床特点未能预测疗效;中位无进展生存时间67月,中位生存时间16.7月。主要不良反应为1~2级骨髓抑制和胃肠道反应;多因素分析示吸烟状况、远处器官转移数目、肝脏转移、化疗周期数是影响预后的独立因素。结论GP方案治疗晚期NSCLC具有较高的疗效,不良反应低。吸烟、远处器官转移数目1个以上、肝脏转移是晚期NSCLC预后不良的因素;GP方案化疗4~6个周期能明显改善预后。

关 键 词:非小细胞肺癌  化疗  治疗结果  预后  
收稿时间:2010-12-31;

Curative Analysis of Gemcitabine Plus Cisplatin for First Line Treatment of Advanced Non-small Cell Lung Cancer
WANG Qiu-ming,LIN Ying-cheng,LIN Wen,WANG Hong-biao,LIN Wen-zhao,LIN Sui-ling.Curative Analysis of Gemcitabine Plus Cisplatin for First Line Treatment of Advanced Non-small Cell Lung Cancer[J].Cancer Research on Prevention and Treatment,2011,38(8):940-943.
Authors:WANG Qiu-ming  LIN Ying-cheng  LIN Wen  WANG Hong-biao  LIN Wen-zhao  LIN Sui-ling
Institution:Department of Medical Oncology, Cancer Hospital of Shantou University,Shantou 515031, China (*Present:Department of Medical Oncology, People Hospital of Meizhou,Meizhou 514031 ,China)
Abstract:Objective To evaluate the curative effect and toxicities of gemcitabine plus cisplatin to therapy patients with advanced non-small cell lung cancer and identify factors to predict prognosis.Methods 113 patients staged IIIB~IV NSCLC were received gemcitabine plus cisplatin as first line treatment.Response rates and toxicities were evaluated in patients who completed at least two cycles of chemotherapy.Progression free survival(PFS) and Overall survival(OS) were estimated using the Kaplan-Meier estimator.Cox ...
Keywords:Non-Small Cell Lung Carcinoma  Chemotherapy  Treatment outcome  Prognosis  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号